慢性全包裹性皮肤冠状动脉干预中的周围手术死亡率:来自PROGRESS-CTO注册表的见解
Bahadir Simsek1, Athanasios Rempakos1, Spyridon Kostantinis1
1Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, MN (B.S., A.R., S.K., J.K., O.C.M., B.V.R., S.S.A., Y.S., M.N.B., E.S.B.).
Circulation. Cardiovascular interventions
|June 1, 2023
概括
死亡是慢性全封闭 (CTO) 穿皮冠状动脉干预的罕见并发症. 根据PROGRESS-CTO注册,0.4%的患者死亡,其中吸水器是主要原因,这凸显了风险分层的必要性.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 慢性全封闭 (CTO) 皮肤冠状动脉干预 (PCI) 与罕见但严重的并发症有关.
- 在CTO PCI的指数住院期间的患者死亡率是理解的关键结果.
研究的目的:
- 调查在CTO PCI期间经历了周围手术死亡的患者的临床特征和程序结果.
- 在这个患者队列中确定风险因素和死亡原因.
主要方法:
- 来自研究CTO干预的前性全球注册表 (PROGRESS-CTO) 的数据分析.
- 死亡患者和幸存者之间的临床和程序因素的比较 CTO PCI.
- 评价特定的评分系统 (J-CTO,PROGRESS-CTO死亡率和心脏切开术) 和程序策略.
主要成果:
- 在12,928名患者中,有52名患者 (0.4%) 在CTO PCI的指数住院期间死亡.
- 死亡的患者更有可能有心力衰竭史和更高的J-CTO,PROGRESS-CTO死亡率和心脏衰竭分数.
- 心脏病原因占主导地位,心脏栓塞 (58%) 是最常见的死亡原因,其次是急性心肌梗塞和心脏骤停.
结论:
- 在CTO PCI后的死亡率低 (0.4%),但显著.
- 较高的并发症评分和特定的患者特征与死亡风险增加有关.
- PROGRESS-CTO并发症分数可以帮助CTO PCI的风险分层和程序规划.
更多相关视频
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.5K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.5K
相关概念视频
01:30Acute Coronary Syndrome III: Diagnostic Studies
12
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
12
01:27Coronary Artery Disease V: Interprofessional Care
12
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
12